Search
Congress Materials
RELISTOR®
(methylnaltrexone bromide) 150 mg tablets
Tablets
Multinational Association of Supportive Care in Cancer (MASCC) and the International Society of Oral Oncology (ISOO) Annual Meeting on Supportive Care in Cancer—June 24–26, 2021, Virtual
Rescue-free laxation response with methylnaltrexone treatment in cancer patients with opioid-induced constipation: the impact of baseline ECOG status
Boniol S, et al.
4th Meeting of the Federation of Neurogastroenterology and Motility—March 25–28, 2020, Adelaide, Australia
PAMORAs result in clinically significant improvement in spontaneous and complete spontaneous bowel movements with low risk of side effects in patients with opioid induced constipation: systematic review and meta-analysis
Vijayvargiya P, et al.
American Academy of Hospice and Palliative Medicine (AAHPM): State of the Science in Hospice and Palliative Care 2020—March 20–22, 2020, Meeting Cancelled
Prevention and treatment of chronic and opioid-induced constipation in patients with cancer: a systematic review and meta-analysis
Ginex P, et al.
American College of Gastroenterology (ACG) Annual Scientific Meeting 2017—October 13–18, 2017, Orlando, FL
Effectiveness of various treatment agents for opioid-induced constipation: a meta-analysis
Saleem R, et al.
PAINWeek 2017—September 5–9, 2017, Las Vegas, NV
Safety of oral methylnaltrexone in patients with opioid-induced constipation and chronic noncancer pain: results from a phase 3, randomized, controlled trial
Rauck R, et al.
Treatment-emergent adverse events related to cardiac safety in a phase 3, randomized, controlled trial of oral methylnaltrexone in patients with opioid-induced constipation and chronic noncancer pain
Rauck R, et al.
Analgesia maintenance with oral methylnaltrexone in patients with opioid-induced constipation and chronic noncancer pain in a phase 3, randomized, controlled trial
Rauck R, et al.
American Pain Society (APS) Annual Scientific Meeting 2017—May 17–20, 2017, Pittsburgh, PA
Oral methylnaltrexone for adults with chronic noncancer pain and opioid-induced constipation (OIC): timing and characterization of clinical symptoms do not suggest opioid withdrawal with daily treatment
Rauck R, et al.
Digestive Disease Week (DDW) 2017—May 6–9, 2017, Chicago, IL
Use of methylnaltrexone in cancer patients with peritoneal carcinomatosis
Nelson KK, et al.
American Academy of Pain Medicine (AAPM) Annual Meeting 2017— March 16–19, 2017, Orlando, FL
Analysis of impact of oral methylnaltrexone for opioid-induced constipation (OIC) on opioid analgesia and withdrawal symptoms in patients with chronic noncancer pain (CNCP) taking methadone [abstract 244]
Webster L, et al.
PAINWeek 2016—September 6–10, 2016, Las Vegas, NV
Peripherally acting mu-opioid receptor antagonists (PAMORAs) for constipation associated with chronic opioid therapy
Pergolizzi JV, et al.
Oral methylnaltrexone is efficacious and well tolerated for the treatment of opioid-induced constipation in patients with chronic noncancer pain taking concomitant methadone
Webster L, et al.
Search
*Required field.
Select a product*
Select a therapeutic area*
Enter keyword(s)